# A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

> **NCT05387733** · PHASE2 · COMPLETED · sponsor: **Caliway Biopharmaceuticals Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Dercum's Disease

## Interventions

- **DRUG:** 10 mg CBL-514 per injection
- **DRUG:** 15 mg CBL-514 per injection

## Key facts

- **NCT ID:** NCT05387733
- **Lead sponsor:** Caliway Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-03
- **Primary completion:** 2023-04-03
- **Final completion:** 2023-04-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387733, "A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05387733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*